Alzheimer’s: How a Muscle Hormone Could Change Everything

Alzheimer’s disease: it’s a diagnosis that strikes fear into the hearts of patients and their loved ones alike.

And despite decades of research and countless efforts to find a cure, Alzheimer’s remains an elusive foe, leaving families to watch helplessly as their loved ones slip away.

But while we may not have a cure yet, that doesn’t mean we’re not making progress.

Every bit of information we learn about Alzheimer’s—from its underlying causes to potential new biomarkers—is crucial to the trajectory of treatment and brings us one step closer to that cure.

And now, a new study has identified a surprising player in the fight against Alzheimer’s: a muscle hormone.

Irisin, which is released by muscles during physical exercise, has been making waves in the Alzheimer’s research community.

A recent study, published in the journal Annals of Neurology, found that levels of irisin in the cerebrospinal fluid (CSF) of patients with Alzheimer’s disease were significantly lower than those in individuals with mild cognitive impairment or subjective memory complaints.

But what does this mean, exactly? Well, think of irisin as a sort of “exercise messenger.” When you engage in physical activity, your muscles release irisin, which then travels throughout your body, including to your brain.

Previous studies show that increased irisin levels in the brain are associated with improved cognitive function and reduced levels of amyloid beta, a protein that forms the hallmark “plaques” found in the brains of Alzheimer’s patients.

In this new study, researchers found that CSF irisin levels were positively correlated with levels of amyloid beta 1-42 (Abeta42), another well-established Alzheimer’s biomarker.

In other words, the lower the irisin levels, the lower the Abeta42 levels—a pattern that’s consistent with the progression of Alzheimer’s disease.

Interestingly, the study also revealed a sex-specific difference in irisin levels. Among patients with Alzheimer’s, women had significantly lower CSF irisin levels than men.

Furthermore, in female patients, irisin levels were negatively correlated with scores on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB), a measure of cognitive impairment severity.

This suggests that irisin may play a particularly important role in the progression of Alzheimer’s in women.

So, what does all of this mean for the future of Alzheimer’s treatment and prevention?

While more research is needed, these findings offer a glimpse into the potential of this hormone as both a biomarker and a therapeutic target.

Imagine, for example, a future where a simple CSF test could help doctors identify individuals at high risk for Alzheimer’s, allowing for earlier intervention and potentially better outcomes. Or a world where targeted therapies aimed at boosting irisin levels could slow, or even halt, the progression of this devastating disease.

Of course, we’re not there yet.

But studies like this one bring us closer every day. And in the meantime, there’s one thing we can all do to potentially harness the power of irisin: exercise. By staying physically active, we may be giving our brains a boost of this protective hormone, helping to keep our minds sharp and our memories intact as we age.

To a world without Alzheimer’s,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Zapping Alzheimer’s with sound waves? Find out here.

Sources:

Irisin Shows Potential as Alzheimer’s Disease Biomarker. (n.d.). Medscape. Retrieved June 12, 2024, from https://www.medscape.com/s/viewarticle/irisin-shows-potential-alzheimers-disease-biomarker-2024a1000azf